Patent ID: 8563583

Claim:
A compound having the following formula: or a pharmaceutically acceptable salt or prodrug thereof; wherein, A 1 and A 2 are independently C or N; D 1 is a bond, —CR 8 R 9 X—, —XCR 8 R 9 —, —CHR 8 CHR 9 —, —CR 10 ═CR 10′ —, —C≡C—, or 1,2-cyclopropyl; X is O, S, SO 2 or —NR 11 ; R 1 , R 2 , and R 3 are independently selected from the group consisting of hydrogen, halogen, —CN, substituted or unsubstituted C 1 to C 4 alkyl, substituted or unsubstituted C 3 to C 5 cycloalkyl, substituted or unsubstituted C 3 to C 5 cycloalkoxy, —CF 3 , —OCF 3 , —OCHF 2 , —OCF 2 CHF 2 , —OR 12 , substituted or unsubstituted phenyl and —SR 12 ; G is O or S; D 2 is substituted or unsubstituted C 2 to C 4 alkyl, substituted or unsubstituted C 3 to C 5 cycloalkyl, substituted or unsubstituted C 3 to C 5 cycloalkoxy, substituted or unsubstituted C 2 to C 3 alkyl-C 3 to C 5 cycloalkyl, substituted or unsubstituted C 1 to C 3 alkyl-C 3 to C 5 cycloalkoxy; Z 1 and Z 2 are independently hydrogen, halogen, substituted or unsubstituted C 1 to C 3 alkyl, substituted or unsubstituted C 3 to C 5 cycloalkyl, —OCH 3 , substituted or unsubstituted C 3 to C 5 cycloalkoxy, halo, —CH 2 SO 2 -alkyl, hydroxyalkyl, —CF 3 , —OCONR 14 R 14′ , —CN, —CONR 14 R 14′ , —SOR 12 , —SO 2 R 12 , —NR 14 COR 14′ , —NR 14 CO 2 R 14′ , —CO 2 R 12 , NR 14 SO 2 R 12 or —COR 12 provided that if Z 1 is —CH 3 and one of R 1 , R 2 , or R 3 is F, then Z 2 cannot be H; R 5 is independently selected from the group consisting of halogen, substituted or unsubstituted C 1 to C 4 alkyl, substituted or unsubstituted C 3 to C 5 cycloalkyl, substituted or unsubstituted C 3 to C 5 cycloalkoxy, —CF 3 , —SR 12 , —OCH 3 , —OCH 2 CH 3 , —OCH 2 OMe, —CN, —CONR 14 R 14′ , SOR 12 , SO 2 R 12 , NR 14 COR 14′ , NR 14 CO 2 R 12 , CO 2 R 12 , NR 14 SO 2 R 12 and —COR 12 ; R 6 , and R 7 are independently selected from the group consisting of hydrogen, halogen, substituted or unsubstituted C 1 to C 4 alkyl, substituted or unsubstituted C 3 to C 5 cycloalkyl, substituted or unsubstituted C 3 to C 5 cycloalkoxy, —CF 3 , —SR 12 , —OCH 3 , —OCH 2 CH 3 , —OCH 2 OMe, —CN, —CONR 14 R 14′ , SOR 12 , SO 2 R 12 , NR 14 COR 14′ , NR 14 CO 2 R 12 , CO 2 R 12 , NR 14 SO 2 R 12 and —COR 12 ; R 8 , R 9 , R 10 , R 10′ , R 11 are independently hydrogen or —CH 3 ; R 12 is substituted or unsubstituted C 1 to C 4 alkyl, substituted or unsubstituted C 3 to C 5 cycloalkyl or phenyl; R 14 and R 14′ are independently H, substituted or unsubstituted C 1 to C 3 alkyl, substituted or unsubstituted C 3 to C 5 cycloalkyl or R 14 and R 14′ together with the N to which they are attached form a ring having 4 to 7 atoms; and wherein the prodrugs of the compounds of said formula are selected from the group consisting of amino acid esters, monoesters of dicarboxylic acids and monoesters of phosphoric acid and incorporate the hydroxyl group that is attached to D 2 .